Page 6 - HIV/AIDS Guidelines

Table of Contents

What’s New in the Guidelines? ..............................................................................................................i

Guidelines Panel Roster .......................................................................................................................vii

Financial Disclosure..............................................................................................................................ix
Introduction..........................................................................................................................................A-1
Table 1. Outline of the Guidelines Development Process...........................................................A-2

Table 2. Rating Scheme for Recommendations...........................................................................A-3
Baseline Evaluation.............................................................................................................................B-1

Laboratory Testing...............................................................................................................................C-1
Laboratory Testing for Initial Assessment and Monitoring
While on Antiretroviral Therapy.................................................................................................C-1
Table 3. Laboratory Monitoring Schedule for Patients Prior to and
After Initiation of Antiretroviral Therapy..............................................................................C-2
CD4 T-Cell Count .......................................................................................................................C-4
Plasma HIV RNA Testing ...........................................................................................................C-6
Drug-Resistance Testing..............................................................................................................C-8

Table 4. Recommendations for Using Drug-Resistance Assays..........................................C-12
HLA-B*5701 Screening............................................................................................................C-16
Coreceptor Tropism Assays.......................................................................................................C-18

Treatment Goals...................................................................................................................................D-1
Initiating Antiretroviral Therapy in Treatment-Naive Patients ...................................................E-1

What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient.................F-1
Table 5a. Preferred and Alternative Antiretroviral Regimens
for Antiretroviral Therapy-Naive Patients...................................................................................F-3
Table 5b. Acceptable Antiretroviral Regimens for Treatment-Naive Patients.............................F-4

Table 6. Advantages and Disadvantages of Antiretroviral Components
Recommended as Initial Antiretroviral Therapy .......................................................................F-16
Table 7. Antiretroviral Components or Regimens Not Recommended as Initial Therapy.........F-20

What Not to Use ...................................................................................................................................G-1
Table 8. Antiretroviral Regimens or Components That Should Not Be Offered At Any Time.....G-3

Management of the Treatment-Experienced Patient.....................................................................H-1
Virologic and Immunologic Failure............................................................................................H-1
Regimen Simplification ............................................................................................................H-11

Exposure-Response Relationship and Therapeutic Drug Monitoring
(TDM) for Antiretroviral Agents...............................................................................................H-15

Table 9a. Trough Concentrations of Antiretroviral Drugs for Patients
Who Have Drug-Susceptible Virus .....................................................................................H-17

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents iv

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.